Shares of TG Therapeutics, Inc. (NASDAQ:TGTX – Get Free Report) crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $31.96 and traded as high as $39.94. TG Therapeutics shares last traded at $39.48, with a volume of 1,602,642 shares.
Wall Street Analyst Weigh In
A number of analysts have weighed in on the stock. Zacks Research cut shares of TG Therapeutics from a “hold” rating to a “strong sell” rating in a report on Friday, May 1st. JPMorgan Chase & Co. cut their target price on TG Therapeutics from $49.00 to $46.00 and set an “overweight” rating on the stock in a research report on Monday, February 2nd. Weiss Ratings upgraded TG Therapeutics from a “hold (c)” rating to a “hold (c+)” rating in a research report on Friday, May 1st. Wall Street Zen cut TG Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. Finally, HC Wainwright lifted their target price on TG Therapeutics from $60.00 to $70.00 and gave the stock a “buy” rating in a research report on Wednesday, May 6th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, TG Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $52.50.
Get Our Latest Research Report on TG Therapeutics
TG Therapeutics Price Performance
TG Therapeutics (NASDAQ:TGTX – Get Free Report) last issued its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.23 by ($0.11). The business had revenue of $204.92 million for the quarter, compared to analysts’ expectations of $200.33 million. TG Therapeutics had a return on equity of 88.73% and a net margin of 65.95%.The company’s revenue for the quarter was up 69.5% on a year-over-year basis. During the same period in the previous year, the business posted $0.03 earnings per share. As a group, sell-side analysts anticipate that TG Therapeutics, Inc. will post 1.31 earnings per share for the current year.
Hedge Funds Weigh In On TG Therapeutics
Several institutional investors have recently added to or reduced their stakes in TGTX. Danske Bank A S acquired a new position in TG Therapeutics in the 3rd quarter valued at $25,000. Optiver Holding B.V. increased its stake in TG Therapeutics by 3,485.7% in the 3rd quarter. Optiver Holding B.V. now owns 753 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 732 shares during the period. Bessemer Group Inc. increased its stake in TG Therapeutics by 117.1% in the 3rd quarter. Bessemer Group Inc. now owns 901 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 486 shares during the period. EverSource Wealth Advisors LLC increased its stake in TG Therapeutics by 51.9% in the 1st quarter. EverSource Wealth Advisors LLC now owns 1,068 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 365 shares during the period. Finally, Hantz Financial Services Inc. increased its stake in TG Therapeutics by 82.7% in the 4th quarter. Hantz Financial Services Inc. now owns 1,237 shares of the biopharmaceutical company’s stock valued at $37,000 after buying an additional 560 shares during the period. Institutional investors and hedge funds own 58.58% of the company’s stock.
TG Therapeutics Company Profile
TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.
In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.
Featured Stories
- Five stocks we like better than TG Therapeutics
- From Zepbound to Foundayo: Lilly’s Latest Results Support Oral GLP-1 Outlook
- AI Consolidation Begins: Blackstone & Google Forge an AI Empire
- USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms
- 3 Space Infrastructure Stocks Gaining Momentum Ahead of the SpaceX IPO
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
